Kära hjälplinje: Comstock-bidrag

Av Mike Mooney | 4 juli 2025 |
Graphic Text: Dear HelpLine - Comstock Grants | Background: A jar of assorted change overflows onto a table

Dear HelpLine, We recently joined an FTD support group, which has been so helpful. The support group volunteer told us about AFTD’s Comstock Grants. Can you help us learn more? Living with FTD brings significant changes for both persons diagnosed and their care partners. As symptoms emerge — behavioral changes, language challenges, cognitive shifts —…

Läs mer

Främjar hopp; AFTD deltar i Tau Global Conference

Av Mike Mooney | 4 juli 2025 |
Text: Advancing Hope - AFTD Attends the Tau Global Conference | Background: A photo of AFTD staff members Drs Nicole Bjorklund and Katherine Still at the 2025 Taul Global Conference

In late April, AFTD Research team members attended a premier conference focused exclusively on research into tau, a protein which is aggregated in Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), MAPT Frontotemporal Degeneration, Alzheimer’s Disease, and other neurodegenerative disorders. This conference was co-hosted by the Alzheimer’s Association, CurePSP, and the Rainwater Charitable Foundation. It brought…

Läs mer

Hjärnpatologi överensstämmande med FTD funnen hos ungefär 351 TP3T av fall av motorneuronsjukdom i en nyligen genomförd studie

Av Mike Mooney | 2 juli 2025 |
Graphic Text: Brain Pathology Consistent with FTD Found in Roughly 35% of Motor Neuron Disease Cases in Recent Study

According to a recent study published in the research journal Brain, brain pathology consistent with FTD was detected in roughly 35% of the participants with motor neuron disease, which includes diseases like ALS. Abnormal protein clumps were detected in 90% of the samples studied, with participants classified as having both FTD and motor neuron disease…

Läs mer

Lovande FTD-genterapi från AviadoBio presenterad i UK Guardian

Av Matt Ozga | 1 juli 2025 |

In London’s Docklands, British biotech company AviadoBio is developing a promising gene therapy to treat FTD. The Guardian wrote about the company’s progress on June 13. AviadoBio’s lead therapy, AVB-101, targets the specific genetic form FTD-GRN, caused by mutations that create a deficiency in progranulin, a protein essential for healthy brain cells. The treatment represents…

Läs mer

FTD Science Digest: Hjälp till att främja vetenskapen genom att gå med i det uppdaterade registret över FTD-störningar

Av Mike Mooney | 1 juli 2025 |
Banner Text: Help Advance Science by Joining the Updated FTD Disorders Registry

It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…

Läs mer

2:a årliga Jim Tobin Memorial Golfturneringen

Av Julie Sullivan | 26 juni 2025 |

AFTD-ambassadör Dawn O'Gara kommer att vara värd för den andra årliga Jim Tobin Memorial Golf Tournament den 28 september 2025, där alla intäkter doneras till AFTD for Research. Turneringen kommer att hållas på Raceway Golf Club i Thompson, Connecticut. Kostnaden är $500 per kvartslag, eller $40 för endast middagsbuffé. Anmälningsavgiften inkluderar 18 hål golf, green…

Läs mer